The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
- D.I. Swerdlow
- M.V. Holmes
- K.B. Kuchenbaecker
- J.E. Engmann
- T. Shah
- R. Sofat
- Y. Guo
- C. Chung
- A. Peasey
- R. Pfister
- S.P. Mooijaart
- H.A. Ireland
- M. Leusink
- C. Langenberg
- K. Li
- J. Palmen
- P. Howard
- J.A. Cooper
- F. Drenos
- J. Hardy
- M.A. Nalls
- Y.R. Li
- G. Lowe
- M. Stewart
- S.J. Bielinski
- J. Peto
- N.J. Timpson
- J. Gallacher
- M. Dunlop
- R. Houlston
- I. Tomlinson
- I. Tzoulaki
- J. Luan
- J.M. Boer
- N.G. Forouhi
- N.C. Onland-Moret
- Y.T. van der Schouw
- R.B. Schnabel
- J.A. Hubacek
- R. Kubinova
- M. Baceviciene
- A. Tamosiunas
- A. Pajak
- R. Topor-Madry
- S. Malyutina
- D. Baldassarre
- B. Sennblad
- E. Tremoli
- U. de Faire
- L. Ferrucci
- S. Bandenelli
- T. Tanaka
- J.F. Meschia
- A. Singleton
- G. Navis
- I. Mateo Leach
- S.J. Bakker
- R.T. Gansevoort
- I. Ford
- S.E. Epstein
- M.S. Burnett
- J.M. Devaney
- J.W. Jukema
- R.G. Westendorp
- G.J. de Borst
- Y. van der Graaf
- P.A. de Jong
- A.H. Maitland-van der Zee
- O.H. Klungel
- A. de Boer
- P.A. Doevendans
- J.W. Stephens
- C.B. Eaton
- J.G. Robinson
- J.E. Manson
- F.G. Fowkes
- T.M. Frayling
- J.F. Price
- P.H. Whincup
- R.W. Morris
- D.A. Lawlor
- G.D. Smith
- Y. Ben-Shlomo
- S. Redline
- L.A. Lange
- M. Kumari
- N.J. Wareham
- W.M. Verschuren
- E.J. Benjamin
- J.C. Whittaker
- A. Hamsten
- F. Dudbridge
- J.A. Delaney
- A. Wong
- D. Kuh
- R. Hardy
- B.A. Castillo
- J.J. Connolly
- P. van der Harst
- E.J. Brunner
- M.G. Marmot
- C.L. Wassel
- S.E. Humphries
- P.J. Talmud
- M. Kivimaki
- F.W. Asselbergs
- M. Voevoda
- M. Bobak
- H. Pikhart
- J.G. Wilson
- H. Hakonarson
- A.P. Reiner
- B.J. Keating
- N. Sattar
DOIAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthrit...
Add to ORKG